Ann Fiegen Durbin

Title: Ann Fiegen Durbin: Innovator in Oligonucleotide Technologies

Introduction

Ann Fiegen Durbin is a prominent inventor based in Arlington, MA (US). She has made significant contributions to the field of biotechnology, particularly in the development of oligonucleotide compositions and their applications in treating genetic disorders.

Latest Patents

Ann Fiegen Durbin holds a patent for "Oligonucleotide compositions and methods of use thereof." This patent encompasses designed DMD oligonucleotides, compositions, and methods that are instrumental in repairing mutant DMD transcripts. The technologies disclosed in her patent are aimed at skipping exon 51 or exon 53, allowing for the translation of an internally truncated but partially functional Dystrophin protein variant. Additionally, her work includes methods for modulating DMD transcript splicing, which can be crucial in treating diseases such as muscular dystrophy, including Duchenne muscular dystrophy and Becker's muscular dystrophy.

Career Highlights

Ann is currently associated with Wave Life Sciences Ltd., where she continues to advance her research and innovations in the field of genetic therapies. Her work is pivotal in developing new treatment methodologies for debilitating muscular disorders.

Collaborations

Some of her notable coworkers include Jason Jingxin Zhang and Chandra Vargeese, who contribute to the collaborative efforts in her research endeavors.

Conclusion

Ann Fiegen Durbin's innovative work in oligonucleotide technologies represents a significant advancement in the treatment of genetic disorders. Her contributions are paving the way for new therapeutic strategies that could improve the lives of many individuals affected by muscular dystrophy.